Pegylated interferon lambda (pegIFN,) phase 2 dose-ranging, active-controlled study in com- bination with ribavirin (RBV) for treatment-naive HCV patients ( genotypes 1,2,3, or 4) : safety, viral response, and impact of IL- 28B host genotype through week 12

查看全文 作　　者：Muir A; Lawitz E; Ghalib R; 出　　处：《Hepatology》索引2010年第52卷第1期,共0页